Boots Healthcare International (BHI) has brought in ex-Kellogg marketing
director Rob Morgan to head the marketing of its global pharmaceutical
brands and spearhead a move into new international markets.
Morgan, who will leave his current role as managing director of Turtle
Wax at Christmas, becomes strategic marketing director at BHI. He is to
head development of the firm’s three major brands, Strepsils, E45 Cream
and Nurofen, in the 130 countries the firm operates in.
He will head five category groups covering the three brands, plus new
product development and public relations. BHI employs around 100
Liz Morgan, the former Carlsberg-Tetley marketing director who joined
BHI in February, will report to Morgan (no relation). She is head of the
cough throat division, which markets the Strepsils brand.
Rob Morgan, 38, was regarded as one of the industry’s most senior
figures during his eight years marketing Kellogg’s brands in the UK.
His move to Turtle Wax last year was unexpected, given his senior FMCG
experience gained at Kellogg, and previously at Cadbury Schweppes and
He joins BHI as the company is investing heavily in acquisitions and new
product development. In September it paid pounds 115m for one of
France’s leading skincare makes, Lutsia, while in June it invested
pounds 12m in the purchase of two skincare brands in Australia.
The company has put pounds 74.1m into NPD in the past year. Although it
recorded losses of pounds 8.3m last year, sales grew by 10.8% to pounds
Morgan replaces Peter Milburn, who left in May to take charge of Boots’
Crookes Healthcare, BHI’s UK subsidiary, spends pounds 10.6m (Register-
MEAL) on Nurofen and Strepsils through McCann-Erickson and BMP DDB